Numerai GP LLC Invests $296,000 in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Numerai GP LLC acquired a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,724 shares of the company's stock, valued at approximately $296,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its position in shares of Pacira BioSciences by 16.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company's stock worth $9,462,000 after buying an additional 70,307 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after purchasing an additional 2,749 shares during the period. Empowered Funds LLC raised its position in shares of Pacira BioSciences by 5.1% in the fourth quarter. Empowered Funds LLC now owns 229,485 shares of the company's stock valued at $4,323,000 after purchasing an additional 11,149 shares during the period. LPL Financial LLC acquired a new stake in shares of Pacira BioSciences in the fourth quarter worth $251,000. Finally, Norges Bank bought a new stake in shares of Pacira BioSciences during the 4th quarter worth $2,405,000. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Price Performance

PCRX stock traded down $0.18 during midday trading on Wednesday, reaching $26.57. 196,982 shares of the company's stock traded hands, compared to its average volume of 969,263. The company has a 50-day simple moving average of $25.04 and a two-hundred day simple moving average of $22.54. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $31.64. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -13.09 and a beta of 0.56.

Analysts Set New Price Targets

Several analysts recently weighed in on PCRX shares. Needham & Company LLC decreased their target price on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Barclays lifted their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. HC Wainwright increased their price objective on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research note on Tuesday, April 8th. Finally, Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and raised their price target for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Pacira BioSciences presently has a consensus rating of "Hold" and a consensus price target of $26.44.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.